Overview

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.
Phase:
Phase 1
Details
Lead Sponsor:
Puma Biotechnology, Inc.
Treatments:
Capecitabine